Acasă › Cancer pulmonar cu celule non-pătrate › Virginia › Alexandria
Studii clinice pentru Cancer pulmonar cu celule non-pătrate în Alexandria, VA
11 studii pentru Cancer pulmonar cu celule non-pătrate caută participanți în și în jurul orașului Alexandria (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
În curs de recrutareFaza 3
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · La 15 mi distanță
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
În curs de recrutareFaza 3
- Maryland Oncology Hematology, PA, Brandywine · La 13 mi distanță
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
În curs de recrutareFaza 3
- Maryland Oncology Hematology, P.A., Brandywine · La 13 mi distanță
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
În curs de recrutareFaza 3
- Research Site, Fort Belvoir · La 8 mi distanță
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
În curs de recrutareFaza 2/3
- Local Institution - 007-814-A, Alexandria
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
În curs de recrutareFaza 3
- Research Site, Brandywine · La 13 mi distanță
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
În curs de recrutareFaza 3
- Research Site, Fort Belvoir · La 8 mi distanță
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
În curs de recrutareFaza 3
- Inova Alexandria Hospital, Alexandria
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · La 15 mi distanță
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2/3
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · La 15 mi distanță
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
În curs de recrutareFaza 2
- Kaiser Permanente-Caton Hill Medical Center, Woodbridge · La 15 mi distanță
Studii pentru Cancer pulmonar cu celule non-pătrate în alte orașe
- Houston, TX145 studii
- New York City, NY121 studii
- Arlington, VA104 studii
- Nashville, TN97 studii
- Boston, MA90 studii
- Los Angeles, CA87 studii
- St. Louis, MO73 studii
- Chicago, IL61 studii
- Baltimore, MD60 studii
- San Antonio, TX59 studii
- Columbus, OH57 studii
- Washington, DC55 studii
Alte studii în Alexandria
- Cancer pulmonar7 studii
- Cancer de sân6 studii
- Diabet de tip 25 studii
- Ateroscleroză5 studii
- Boli cardiovasculare5 studii
- Cancer de colon4 studii
- Hipertensiune arterială4 studii
- Obezitate4 studii
- Cancer gastric3 studii
- Cancer colorectal3 studii
- Supraponderalitate3 studii
- Accident vascular cerebral3 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.